Introduction
============

Hypertension remains a global health challenge as its prevalence continues to grow rapidly in both developed and developing countries.[@b1-vhrm-12-407] This chronic condition requires long-term treatment, and is deemed responsible for 12.8% of deaths worldwide.[@b2-vhrm-12-407] Strong evidence from randomized controlled trials has revealed that treatment of high blood pressure significantly decreases cardiovascular disease (CVD)-associated morbidity and mortality.[@b3-vhrm-12-407],[@b4-vhrm-12-407] A recent clinical trial associated the reductions of 3.8 mmHg and 1.5 mmHg in systolic and diastolic pressure, respectively, to a 37% decrease in the development of left ventricular hypertrophy as well as a 50% decrease in CVD events.[@b5-vhrm-12-407] To achieve such positive outcomes, long-term adherence to antihypertensive treatment is essential.[@b6-vhrm-12-407] Over the last few years, new antihypertensive drugs with lower incidence of adverse events have been developed.[@b7-vhrm-12-407] Despite the significant improvement in medical therapies, the lack of adherence to these treatments remains a clinical challenge considering the serious health risks associated with high blood pressure and its heavy burden on the public health. Adherence is defined by the World Health Organization as "the extent to which a person's behavior -- taking medication, following a diet, and/or executing lifestyle changes -- corresponds with agreed recommendations from a health care provider".[@b8-vhrm-12-407] In fact, poor adherence has been widely recognized among patients on antihypertensive therapy. Consequently, despite appropriate diagnosis and drug prescription, considerable number of patients fail to benefit from the treatment; this results in poor health outcomes and lower quality of life.[@b6-vhrm-12-407]--[@b13-vhrm-12-407] It is important to highlight the role of adherence in improving the outcome of antihypertensive treatments.[@b14-vhrm-12-407] Little is known in Lebanon and Jordan regarding treatment adherence and quality of life in hypertensive patients. We designed an observational study, with the primary objective of assessing antihypertensive treatment adherence in a cohort of hypertensive Jordanian and Lebanese patients newly diagnosed with hypertension, or patients diagnosed with uncontrolled essential hypertension according to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Guidelines criteria,[@b7-vhrm-12-407] and treated with antihypertensive medication for more than 6 months. The study also aimed at identifying potential factors that may alter adherence to antihypertensive treatment, including different therapeutic modalities.

This study provides unique multinational data and a valuable update on the current adherence to antihypertensive therapy in a hypertensive population from Jordan and Lebanon.

Methods
=======

Study design and patients
-------------------------

We conducted an observational study in a cohort of hypertensive patients attending hospitals and private clinics in Lebanon and Jordan between May 2011 and September 2012. Hospitals and clinics were chosen to represent the private and public sectors as well as to cover rural and urban areas. The target survey population included subjects of either sex, aged above 21 years, newly diagnosed with hypertension, or uncontrolled on medication after being treated for 6 months or more. Subjects were approached by their treating physicians and asked about their willingness to participate in the study. Participants had to provide written informed consent and comply with the survey schedule. Exclusion criteria were secondary hypertension, acute illnesses, psychiatric diseases, pregnant women, nursing mothers, and subjects who were unable to provide informed consent. Ethics committee approval was obtained from the American University of Beirut Institutional Review Board and from the Jordan Hospital Institutional Review Board. Since there was no available literature on the prevalence of adherence among Lebanese and Jordanian hypertensive patients at the time of the study design, a 50% expected adherence rate was used. Considering a precision of 4% and a 95% confidence level, the minimum required sample size in each country was 601, and considering a 20% attrition rate the final calculated sample size was 720 subjects per country.

Participants
------------

A total of 1,506 patients gave written informed consent to participate in the study, 750 from Jordan and 756 from Lebanon. Five participants from Jordan and 31 from Lebanon were excluded because they did not fulfill the inclusion criteria. The remaining 1,470 hypertensive patients, 745 from Jordan and 725 from Lebanon, were enrolled in the study.

Procedure
---------

Patients were instructed on how to take their newly prescribed medication, but no interventions targeting adherence took place during the study. Data collection took place during three mandatory visits over 6 months. Patients were seen at study inclusion (V0), at an intermediate visit, 1--3 months after inclusion (VI), and at study end (VE). During the three visits, investigators completed a case report form including the patient's personal information, the physical examination assessment, and the antihypertensive treatment and modality (drug class and monotherapy vs combined therapy). Information regarding the patient's adherence to the antihypertensive treatment was collected during the final visit (VE), while data on quality of life were collected during the first and final visits. Data on sociodemographic characteristics (age, sex, nationality, marital status, education level, work experience, and health care system), family history of CVD, and clinical characteristics including medical history and comorbidities (ischemic heart disease, respiratory disease, and others) were also collected. Blood pressure measurements were classified into normal, prehypertension, stage 1 hypertension, and stage 2 hypertension based on the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines.[@b7-vhrm-12-407] The CVD risk was stratified into five categories: very low, medium low, medium high, high, and very high according to the National Cholesterol Education Program Adult Treatment Panel III guidelines.[@b15-vhrm-12-407] Patients' identity was kept anonymous and was only accessible to the principal investigator.

Outcome measures
----------------

### Morisky, Green & Levine Scale

Adherence was assessed using the Morisky, Green & Levine Scale.[@b16-vhrm-12-407] The scale consists of the following four close-ended questions, which could be answered by YES or NO: 1) Have you ever forgotten to take your medication? 2) Are you, at times, careless regarding the time to take your medication? 3) When you have felt good, have you ever stopped taking your medication? 4) Have you ever failed to take the medicine when you felt ill? A negative answer was graded 1, whereas a positive answer was graded 0. Subjects were considered adherent to treatment if they scored 4 on the Morisky, Green & Levine Scale, and non adherent to their treatment if they scored three or lower.

### Health-related quality of life assessment

The Hypertension Quality of Life Questionnaire (MINICHAL)[@b17-vhrm-12-407] was used. MINICHAL consists of 17 items of which ten are pertinent to the domain of mental status, six to the domain of somatic manifestations, and a last one to the patient's overall perception of his/her quality of life. Items are answered on a 4-point Likert scale ranging from 0 to 3: 0 (No, Never), 1 (Yes, At least once in the past week), 2 (Yes, At least once per day), and 3 (Yes, Several times per day). MINICHAL was created by adding all the scale item scores, and it ranged from 0 to 48 with a lower score indicating the best level of health.[@b18-vhrm-12-407]

Statistical analysis
--------------------

Statistical analyses were performed using the statistical software SPSS Inc. (version 17.0; Chicago, IL, USA). Mean values and standard deviations were used to describe continuous variables, whereas percentages were used to describe categorical variables. Student's *t*-test was used for comparison of means, and Pearson chi-square test (χ^2^) was used for comparison of proportions between groups. A *P*-value \<0.05 was considered statistically significant. A multivariate analysis using logistic regression was carried out taking into account potential confounding variables that had a *P*-value\< 0.1. The dependent variable was adherence to treatment and was binary (YES or NO). Adjusted odds ratios and their 95% confidence intervals were reported. Hosmer and Lemeshow test was used to assess the goodness-of-fit of the regression model. The dependent variable was adherence to treatment and was binary (YES or NO). Adjusted odds ratios (ORs) and their 95% confidence intervals (CIs) were reported.

Results
=======

The study population consisted of 842 (57.3%) males and 628 (42.7%) females. Mean age was 54.7±13.1 years. Of the total, 622 were newly diagnosed with hypertension, and 848 patients had uncontrolled hypertension. The majority of the subjects (80%) were married, and almost half of them (47.7%) had secondary education. Of the total, 754 patients (55.9%) were adherent to treatment, while the remaining 596 (44.1%) were not ([Table 1](#t1-vhrm-12-407){ref-type="table"}). After 6 months of follow-up, the percentage of patients with stage 2 hypertension decreased from 68% to 4.8%. In addition, the percentage of those fitting the high CVD risk category decreased from 7.2% to 2.8% ([Table 2](#t2-vhrm-12-407){ref-type="table"}).

Mean score of the health-related quality of life (MINICHAL) was higher at the first visit (15.1±8.2) than at the final visit (8.7±7.6), suggesting a better quality of life after 6 months of antihypertensive treatment use ([Table 2](#t2-vhrm-12-407){ref-type="table"}).

The bivariate analysis showed that marital status, blood pressure classifications, CVD risk stratification, and health-related quality of life were significantly associated with patient adherence. The percentage of adherent patients was the highest among single patients (62.8%) and the lowest among widowed patients (42.4%) (*P*=0.02) ([Table 1](#t1-vhrm-12-407){ref-type="table"}). Adherence differed significantly by blood pressure categories as assessed at the end of the study (*P*\<0.001). The percentage was the lowest (30.2%) among patients with stage 2 hypertension and the highest among normotensive (67.1%) and pre-hypertensive patients (59.4%). Patients who had a low CVD risk at V0 and VE were more likely to be adherent (67.4% and 64.3%, respectively). Moreover, mean MINICHAL scores at V0 (14.4±8.4) and VE (8.7±7.6) were lower among adherent patients suggesting a better quality of life ([Table 2](#t2-vhrm-12-407){ref-type="table"}). On another note, results showed that adherence was not statistically associated with the modality of antihypertensive treatment (*P*\>0.05).

After controlling for independent variables with *P*-value \<0.1, only age, marital status, blood pressure categories at the end of the study, and health-related quality of life (MINICHAL) remained associated with adherence at the multivariate level. Older patients were more likely to be adherent to antihypertensive treatment (OR 1.01, 95% CI 1.00--1.02). Divorced (OR 0.30, 95% CI 0.15--0.62), and widowed (OR 0.33, 95% CI 0.15--0.70) patients were less likely to be adherent to treatment as compared to single patients. Patients categorized at the end of the study as having stage 1 (OR 0.35, 95% CI 0.19--0.64) or stage 2 (OR 0.47, 95% CI 0.23--0.94) hypertension were also less likely to be adherent as compared to those with normal blood pressure. An increase in the MINICHAL score was associated with lower odds of adherence ([Table 3](#t3-vhrm-12-407){ref-type="table"}).

Discussion
==========

This is the first report that evaluates adherence to treatment and its associated factors among hypertensive patients in Jordan and Lebanon. This study revealed a high percentage of low adherence to antihypertensive drug therapy in Jordan and Lebanon reaching 44%. Older age was associated with better adherence, whereas divorced and widowed status, as well as stage 1 and stage 2 hypertension, and poorer quality of life were associated with poorer adherence.

The adherence rate found in this study was lower than that reported in developed countries such as the US (91%)[@b19-vhrm-12-407] and Scotland (91%).[@b20-vhrm-12-407] Though the latter studies used different adherence assessment measurements, Morisky, Green & Levine Scale in the US and an objective assessment of adherence based on drug supply in Scotland, the observed difference with our study results might be due to the free access to medical care in these countries. However, adherence rate was higher than that in other developing countries such as Palestine (45.7%)[@b21-vhrm-12-407] and Saudi Arabia (27.9%),[@b22-vhrm-12-407] but lower to that in Pakistan (77%).[@b23-vhrm-12-407] The variation in antihypertensive adherence rate reported in developing countries could be explained by the lack of a standardized measurement of adherence, along with the variation in the sampling methodology. Though all the three studies used a subjective assessment of adherence; however, the Hill--Bone medication adherence scale, which was used in the study conducted in Saudi Arabia, not only assesses adherence to medication but also to other behaviors such as reduced sodium intake and appointment keeping. This could have been responsible for the very low adherence rate reported in Saudi Arabia. We found that adherence was significantly associated with age. Our finding is consistent with other papers published by Al-Sowielem and Elzubier, Hashmi et al, and Yiannakopoulou et al.[@b24-vhrm-12-407]--[@b26-vhrm-12-407] This could be explained by the social dynamics of the Arab populations, which are mostly portrayed in close family ties, social support, and respect for the elders. In contrast to senior subjects, younger patients refute the need to be treated for hypertension once diagnosed and deny the necessity for regular drug use. This could be one of the many reasons that lead to drug adherence issues among this age group.[@b27-vhrm-12-407],[@b28-vhrm-12-407]

Marital status was also found to affect adherence. Married participants were as adherent as single patients, while divorced and widowed subjects were less likely to be adherent. This is discordant with the results of a study conducted by Karaeren et al, which reported that married patients were more adherent to treatment (85%) compared to those who were not married (70%), suggesting that spousal help and support improved adherence.[@b29-vhrm-12-407] Adherence was associated with improved quality of life. The decrease in blood pressure to less than 120/80 mmHg was significantly more observed in adherent participants compared to nonadherent patients. Indeed, many publications supported the association between adherence to treatment and a controlled blood pressure[@b26-vhrm-12-407],[@b30-vhrm-12-407]--[@b32-vhrm-12-407] as well as better health outcomes.[@b33-vhrm-12-407]

Despite the abundance of literature reports describing the low rate of adherence among hypertensive patients, no immediate solution has been forwarded to answer this unmet need. However, appropriate follow-up and awareness should be offered to the patients for achieving better health outcomes. Health education by a multidisciplinary team should be provided to such patients.

Consistency of our findings with other literature, the relatively large sample size, the use of a validated tool (Morisky, Green & Levine Scale) to evaluate treatment adherence, and the adjustment for wide determinants of adherence including sociodemographic, clinical, and disease-related characteristics as well as health-related quality of life are all distinctive assets of our study. However, several limitations are worth mentioning, such as the possibility of selection bias secondary to the recruitment of participants from tertiary care hospitals and not from the general population, which limits the generalizability of our findings. Moreover, the reliance on self-reported adherence using Morisky questionnaire rather than on objective measures of adherence, such as drug counts or electronic monitoring, might introduce response bias. Another limitation is the absence of the direct assessment of drug tolerability, which can mask an important aspect that has been extensively shown to be related to adherence.[@b34-vhrm-12-407],[@b35-vhrm-12-407] Though drug tolerability was indirectly measured in the MINICHAL questionnaire, it would have been more informative to explicitly assess this concept in such studies exploring adherence to treatment.

Conclusion
==========

Almost half of the study population was nonadherent to anti-hypertensive medication. Age, marital status, high blood pressure categories (stages 1 and 2), and health-related quality of life were found to be the main factors affecting adherence. Moreover, our study revealed that 6 months of adherence to antihypertensive treatment could improve quality of life as well as blood pressure level among hypertensive Middle Eastern patients.

Future studies should further investigate other sociocultural factors that may affect adherence. Based on the findings of this study, there is a need for planning and implementation of health education campaigns involving health care providers, patients, and the public, with the aim of increasing awareness, improving treatment of high blood pressure, and enhancing adherence to therapy.
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###### 

Baseline characteristics of hypertensive patients by adherence status

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                           All patients\   Nonadherent[a](#tfn1-vhrm-12-407){ref-type="table-fn"}\   Adherent[a](#tfn1-vhrm-12-407){ref-type="table-fn"}\   *P*-value
                                            N=1,470         n=596                                                     n=754                                                  
  ----------------------------------------- --------------- --------------------------------------------------------- ------------------------------------------------------ -----------
  **Sex, n (%)**                                                                                                                                                             

   Male                                     842 (57.3)      343 (44.4)                                                429 (55.6)                                             0.73

   Female                                   628 (42.7)      247 (43.5)                                                321 (56.5)                                             

  **Age, years (mean SD)**                  54.69 (13.1)    54.52 (12.7)                                              55.14 (13.3)                                           0.38

  **Nationality, n (%)**                                                                                                                                                     

   Lebanese                                 704 (47.9)      272 (42.1)                                                374 (57.9)                                             0.09

   Jordanian                                715 (48.7)      299 (45.2)                                                362 (54.8)                                             

   Others                                   50 (3.4)        25 (58.1)                                                 18 (41.9)                                              

  **Marital status, n (%)**                                                                                                                                                  

   Single                                   102 (6.9)       35 (37.2)                                                 59 (62.8)                                              **0.02**

   Married                                  1,175 (80)      464 (43.2)                                                610 (56.8)                                             

   Divorced                                 106 (7.2)       47 (49)                                                   49 (51)                                                

   Widowed                                  86 (5.9)        49 (57.6)                                                 36 (42.4)                                              

  **Level of education, n (%)**                                                                                                                                              

   Primary                                  386 (26.3)      248 (43.4)                                                323 (51.8)                                             0.8

   Secondary                                700 (47.7)      271 (42.3)                                                369 (57.7)                                             

   University                               380 (26)        152 (43.1)                                                201 (56.9)                                             

  **Work status, n (%)**                                                                                                                                                     

   Unemployed                               622 (42.4)      248 (43.4)                                                323 (56.6)                                             0.19

   Employed                                 746 (50.9)      302 (44.2)                                                382 (55.8)                                             

   Retired                                  98 (6.7)        43 (47.3)                                                 48 (52.7)                                              

  **Health care, n (%)**                                                                                                                                                     

   No                                       339 (23.3)      138 (44.1)                                                175 (55.9)                                             0.98

   Yes                                      1,115 (76.7)    452 (44.1)                                                572 (55.9)                                             

  **Current smoking status, n (%)**                                                                                                                                          

   No                                       936 (63.9)      380 (44.1)                                                481 (55.9)                                             0.9

   Yes                                      529 (36.1)      214 (44.1)                                                271 (55.9)                                             

  **Presence of chronic diseases, n (%)**                                                                                                                                    

   No                                       484 (32.9)      194 (43.3)                                                254 (56.7)                                             0.66

   Yes                                      987 (67.1)      402 (44.6)                                                500 (55.4)                                             

  **Family history of CVD, n (%)**                                                                                                                                           

   No                                       841 (57.9)      342 (44.3)                                                430 (55.7)                                             0.9

   Yes                                      611 (42.1)      249 (44.3)                                                313 (55.7)                                             

  **Hypertension diagnosis, n (%)**                                                                                                                                          

   Newly diagnosed                          622 (42.3)      357 (46.2)                                                416 (53.8)                                             0.09

   Uncontrolled                             848 (57.7)      239 (41.5)                                                337 (58.5)                                             

  **Hypertension comorbidities, n (%)**                                                                                                                                      

   No                                       484 (32.9)      194 (43.3)                                                254 (56.7)                                             0.7

   Yes                                      987 (67.1)      402 (44.6)                                                500 (55.4)                                             
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Subjects were considered adherent to treatment if they scored 4 on Morisky, Green & Levine Scale and nonadherent to their treatment if they scored 3 or lower.[@b16-vhrm-12-407] *P*-values were generated from a chi square test in the case of qualitative variables and from a Student's *t*-test in the case of quantitative variables. A *P*-value\<0.05 was considered statistically significant. Statistically significant *P*-values are highlighted in bold.

**Abbreviations:** SD, standard deviation; CVD, cardiovascular disease.

###### 

Blood pressure categories, cardiovascular risk stratification, antihypertensive treatment, and quality of life of patients by adherence status

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                             All patients\   Nonadherent[a](#tfn3-vhrm-12-407){ref-type="table-fn"}\   Adherent[a](#tfn3-vhrm-12-407){ref-type="table-fn"}\   *P*-value
                                              N=1,470         n=596                                                     n= 754                                                 
  ------------------------------------------- --------------- --------------------------------------------------------- ------------------------------------------------------ -------------
  **Blood pressure categories (V0), n (%)**                                                                                                                                    

   Normal                                     0               0                                                         0                                                      0.83

   Prehypertension                            29 (2)          10 (40.0)                                                 15 (60.0)                                              

   Stage 1 hypertension                       437 (29.9)      120 (39.3)                                                185 (60.7)                                             

   Stage 2 hypertension                       997 (68)        257 (41.5)                                                363 (58.5)                                             

  **Blood pressure categories (VE), n (%)**                                                                                                                                    \<**0.001**

   Normal                                     158 (11.5)      50 (32.9)                                                 102 (67.1)                                             

   Prehypertension                            929 (67.4)      363 (40.6)                                                531 (59.4)                                             

   Stage 1 hypertension                       226 (16.4)      119 (56.4)                                                92 (43.6)                                              

   Stage 2 hypertension                       66 (4.8)        44 (69.8)                                                 19 (30.2)                                              

  **CVS (V0), n (%)**                                                                                                                                                          **0.007**

   Low                                        187 (12.8)      31 (32.6)                                                 64 (67.4)                                              

   Medium low                                 461 (31.6)      99 (36.0)                                                 176 (64)                                               

   Medium high                                433 (29.7)      112 (38.5)                                                179 (61.5)                                             

   High                                       273 (18.7)      103 (49.8)                                                104 (50.2)                                             

   Very high                                  107 (7.2)       38 (47.5)                                                 42 (52.5)                                              

  **CVS (VE), n (%)**                                                                                                                                                          \<**0.001**

   Low                                        543 (38.8)      187 (35.7)                                                337 (64.3)                                             

   Medium low                                 497 (35.5)      220 (46.5)                                                253 (53.5)                                             

   Medium high                                228 (16.3)      116 (53.7)                                                100 (46.3)                                             

   High                                       92 (6.6)        48 (53.9)                                                 41 (46.1)                                              

   Very high                                  39 (2.8)        19 (50)                                                   19 (50)                                                

  **Type of treatment (V0), n (%)**                                                                                                                                            0.18

   Monotherapy                                329 (39.8)      135 (36.0)                                                194 (43.0)                                             

   Two combinations                           305 (36.9)      149 (39.7)                                                156 (34.6)                                             

   Three combinations                         147 (17.8)      72 (19.2)                                                 75 (16.6)                                              

   Four combinations                          45 (5.4)        19 (5.1)                                                  26 (5.8)                                               

  **Type of treatment (VE), n (%)**                                                                                                                                            0.22

   Monotherapy                                351 (35.5)      141 (32.3)                                                210 (37.9)                                             

   Two combinations                           356 (36.0)      158 (36.2)                                                198 (35.7)                                             

   Three combinations                         205 (20.7)      100 (22.9)                                                105 (19.0)                                             

   Four combinations                          78 (7.9)        37 (8.5)                                                  41 (7.4)                                               

  **MINICHAL (V0), mean (SD)**                15.1 (8.2)      16.1 (7.8)                                                14.4 (8.4)                                             **0.002**

  **MINICHAL (VE), mean (SD)**                10.6 (8.0)      13.1 (7.8)                                                8.7 (7.6)                                              \<**0.001**
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Subjects were considered adherent to treatment if they scored 4 on Morisky, Green & Levine Scale and nonadherent to their treatment if they scored 3 or lower.[@b16-vhrm-12-407] Blood pressure measurements were classified based on the JNC7 guidelines.[@b7-vhrm-12-407] SBP/DBP (mmHg) \<120/80: normal, 120--139/80--89: prehypertension, 140--159/90--99: stage 1 hypertension, 160--179/100--109: stage 2 hypertension. Cardiovascular risk was stratified into five categories according to the NCEP ATP III guidelines.[@b15-vhrm-12-407] *P*-values were generated from a chi square test in the case of qualitative variables and from a Student's *t*-test in the case of quantitative variables. A *P*-value\<0.05 was considered statistically significant. Statistically significant *P*-values are highlighted in bold.

**Abbreviations:** VO, first visit; VE, final visit; CVS, Cardiovascular Score; MINICHAL, Hypertension Quality of Life Questionnaire; SD, standard deviation; JNC7, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; NCEP ATP III, National Cholesterol Education Program Adult Treatment Panel III.

###### 

OR and 95% CI for factors associated with adherence in hypertensive patients

  Variables                            OR (95% CI)                 *P*-value
  ------------------------------------ --------------------------- -------------
  **Age**                              1.011 (1.001--1.020)        **0.025**
  **Marital status**                                               
   Single                              1.00                        **0.002**
   Married                             0.62 (0.36--1.04)           0.069
   Divorced                            **0.30 (0.15**--**0.62)**   **0.001**
   Widowed                             **0.33 (0.15**--**0.70)**   **0.004**
  **Blood pressure categories (VE)**                               
   Normal                              1.00                        \<**0.001**
   Prehypertension                     0.66 (0.37--1.18)           0.160
   Stage 1 hypertension                **0.35 (0.19**--**0.64)**   **0.001**
   Stage 2 hypertension                **0.47 (0.23**--**0.94)**   **0.034**
  **MINICHAL (VE)**                    **0.93 (0.91**--**0.94)**   \<**0.001**

**Notes:** Blood pressure measurements were classified based on the JNC7 guidelines.[@b7-vhrm-12-407] SBP/DBP (mmHg) \<120/80: normal, 120--129/80--84: prehypertension, 140--159/90--99: stage 1 hypertension, 160--179/100--109: stage 2 hypertension. *P*-values were generated from the logistic regression of the adherence variables on the corresponding covariates. A *P*-value\<0.05 was considered statistically significant. Statistically significant *P*-values are highlighted in bold.

**Abbreviations:** OD, odds ratio; CI, confidence interval; VE, final visit; MINICHAL, Hypertension Quality of Life Questionnaire; JNC7, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure.
